C9093 – Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg

Long description

Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg

Short description

Inj., susvimo, 0.1 mg

Pricing indicator

53 Statute

Medicare coverage

D Special coverage instructions apply

BETOS category

O1E Other drugs

Added

April 1, 2022

Last change

July 1, 2022 – No change

Termination date

June 30, 2022

Nearby C codes

• C9085 – Injection, avalglucosidase alfa-ngpt, 4 mg
• C9086 – Injection, anifrolumab-fnia, 1 mg
• C9087 – Injection, cyclophosphamide, (auromedics), 10 mg
• C9088 – Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg
• C9089 – Bupivacaine, collagen-matrix implant, 1 mg
• C9090 – Injection, plasminogen, human-tvmh, 1 mg
• C9091 – Injection, sirolimus protein-bound particles, 1 mg
• C9092 – Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg
• C9094 – Inj, sutimlimab-jome, 10 mg
• C9095 – Inj, tebentafusp-tebn, 1 mcg
• C9096 – Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram
• C9097 – Inj, faricimab-svoa, 0.1 mg
• C9098 – Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
• C9101 – Injection, oliceridine, 0.1 mg
• C9113 – Injection, pantoprazole sodium, per vial
• C9121 – Injection, argatroban, per 5 mg